Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. (September 2016)

• Record Type: Journal Article
• Authors: Queiroz, Marcelo A.; Viana, Publio; Santos, Allan; Bastos, Diogo; Etchebehere, Elba; Cerri, Giovanni
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 9(2016)
• Publication Date: 2016-09
• Subjects: PET/CT -- 68Ga-PSMA -- prostate cancer -- radical prostatectomy -- biochemical recurrence -- metastasis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001264
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 64-year-old man with history of prostate adenocarcinoma underwent radical prostatectomy in 2003. He remained with undetectable prostate-specific antigen (PSA) levels until 2014, when he then presented rising serum PSA levels and performed a 99m Tc-MDP bone scan that was negative for metastases. In August 2015, his PSA was 4.89 ng/dL, and restaging images with pelvic MR and 18 F-FDG PET/CT were both negative. Therefore, the patient underwent a 68 Ga-PSMA PET/CT that showed marked tracer uptake in a single mediastinal lymph node. Histopathology demonstrated metastatic adenocarcinoma secondary to prostate cancer, altering patient management to hormone therapy instead of pelvic radiotherapy.